Prostate Cancer Therapy

Combination of QUADRAMET and chemotherapy to be evaluated in new clinical trial

Published in Cancer Weekly, February 15th, 2005

Cytogen Corp. (CYTO), a product-driven biopharmaceutical company, announced that researchers at Johns Hopkins Kimmel Cancer Center will investigate the use of QUADRAMET (samarium Sm-153 lexidronam) in combination with docetaxel for the treatment of hormone refractory prostate cancer that has spread to bone.

The clinical study will evaluate the safety profile and preliminary incidence and duration of clinical benefits of novel escalating-dose and administration schedules of docetaxel in combination with multiple doses of QUADRAMET.

"We are appreciative of the support and interest generated by both medical researchers and pharmaceutical companies as...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-02-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry